Engineering immunity: bacterial delivery of cancer neoantigen vaccines

Trends Immunol. 2024 Dec;45(12):931-933. doi: 10.1016/j.it.2024.11.007. Epub 2024 Nov 27.

Abstract

In the battle against cancer, researchers are exploring the use of engineered bacteria as living medicines. Redenti and colleagues demonstrate that Escherichia coli Nissle 1917 (EcN) can be engineered to deliver cancer neoantigen payloads, stimulating antigen-specific CD4+ and CD8+ T cells and mediating antitumor immunity in preclinical models of colorectal cancer and melanoma.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antigens, Neoplasm* / immunology
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / immunology
  • Cancer Vaccines* / immunology
  • Escherichia coli / immunology
  • Humans
  • Immunotherapy / methods
  • Melanoma / immunology
  • Melanoma / therapy
  • Neoplasms / immunology
  • Neoplasms / therapy

Substances

  • Cancer Vaccines
  • Antigens, Neoplasm